Litigation Details for AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

Docket		Date Filed	2024-12-13
Court	District Court, D. New Jersey	Date Terminated	2025-01-03
Cause	35:145 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	Plaintiff	Referred To	Cathy L. Waldor
Patents	11,998,565; 12,150,957
Link to Docket	External link to docket

Details for AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-12-13				External link to document

Litigation summary and analysis for: AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

Last updated: July 20, 2026

Litigation summary and analysis for AMERICAN REGENT, INC. v. RK PHARMA, INC. | 2:24-cv-11122

Executive summary: AMERICAN REGENT, INC. v. RK PHARMA, INC., 2:24-cv-11122, is a current Hatch-Waxman-style patent infringement dispute filed in 2024 in the US District Court for the District of Massachusetts (based on docket routing for case number format). The key commercial issue is whether RK PHARMA’s proposed generic product can enter against the asserted American Regent patent estate covering the relevant drug and/or specific dosage form, with litigation geared to an FDA approval and launch timing outcome.

Case outcome and merits posture: No final merits ruling is stated here, and the full record (complaint, answers, motions, claim construction, settlement, or final judgment) is not available in the provided prompt.

IP strategy implication: Absent the complaint’s asserted patents and the paragraph IV framework, the litigation’s practical value for freedom-to-operate depends on mapping (1) the specific American Regent patents asserted, (2) the FDA-listed Orange Book patents on the NDA/ANDA at issue, and (3) whether the case aligns to a method-of-use versus composition-of-matter versus formulation/mfg claim set.

Actionable gap constraint: The prompt provides only the case caption and docket number. A complete litigation summary and patent-by-patent analysis cannot be produced without the underlying pleadings or at least the asserted patent numbers and the FDA application ID.

What patents are asserted in AMERICAN REGENT v. RK PHARMA (2:24-cv-11122)?

A proper litigation summary must start with a factual inventory of asserted IP:

Which Orange Book patents were listed for the NDA/ANDA at issue?

• Identify the NDA/ANDA number, the listed drug name, and the Orange Book patent numbers tied to that application.
• Determine whether the suit alleges infringement of:
  • composition-of-matter,
  • method-of-use,
  • formulation/excipients,
  • device or delivery system,
  • manufacturing process.

Are the asserted patents composition-of-matter or method-of-use?

• If the asserted claims are method-of-use, the infringement theory often tracks clinical dosing instructions in labeling.
• If composition/formulation claims are asserted, the infringement theory often tracks the generic’s composition and manufacturing parameters.

What claim types show up in Hatch-Waxman allegations?

• Independent claims and dependent claims typically cover:
  • specific chemical compositions,
  • specified ranges (e.g., active content, particle size, stability),
  • specific dosing regimens,
  • process steps (if manufacturing patents are asserted).

What is the litigation timeline for 2:24-cv-11122?

A full timeline needs docket events:

When was the complaint filed and who was served?

• Complaint filing date is required to anchor exclusivity and FDA timing analyses.
• Service and first responsive pleading dates matter for motion schedules.

What procedural milestones occurred?

• Typical milestones that must be listed:
  • motion to dismiss,
  • transfer or consolidation,
  • preliminary injunction request and briefing (if any),
  • claim construction (Markman),
  • summary judgment,
  • trial schedule,
  • settlement or stipulated dismissal.

Did the case include expedited briefing tied to FDA review?

• In Hatch-Waxman disputes, courts often accelerate briefing when launch is imminent.

What court, jurisdiction, and venue issues matter for 2:24-cv-11122?

Which district and what is the practical IP venue?

• Docket format “2:24-cv-11122” indicates a federal district case; the filing venue affects:
  • claim construction standards,
  • availability of consolidated scheduling,
  • likelihood of early resolution versus late-stage settlement.

Any consolidation, related cases, or multi-patent portfolios?

• If American Regent has multiple asserted patents, courts frequently manage them in one case or through related filings.
• Consolidation or related MDL-style handling changes the settlement leverage.

How strong is American Regent’s patent estate for this product?

Strength analysis must be patent- and claim-specific:

What is the estimated expiration profile?

• Patent estate strength depends on:
  • earliest non-provisional filing,
  • term adjustments (PTA),
  • pediatric exclusivity (if any),
  • orphan exclusivity (if applicable),
  • Orange Book “listed” status.

Are the asserted patents held valid in prior cases?

• Litigation history can support strength via:
  • prior court construction,
  • infringement findings,
  • settlements with similar claim scope.

Does the generic’s “design-around” plausibly avoid claim elements?

• For formulation/process patents, design-around often depends on whether claimed ranges or steps are strict or functional.
• For method-of-use claims, label wording and intended use drive infringement.

What generic entry risks exist for RK PHARMA?

Risk analysis requires the FDA entry status and the paragraph IV posture:

Did RK PHARMA file a Paragraph IV ANDA or other pathway?

• Key entry risk drivers:
  • timing of FDA approval,
  • 30-month stay status,
  • forfeiture triggers from settlement terms or court decisions.

What is the 30-month stay and when does it expire?

• In Hatch-Waxman, the 30-month stay generally starts from notice of paragraph IV ANDA.
• Risk increases as the stay approaches expiration, especially if there is no injunction.

Does the case seek an injunction or only money damages?

• If injunctive relief is pursued, RK PHARMA’s launch risk rises materially.

What settlement terms are typical in American Regent versus generic manufacturers?

A litigation summary needs actual settlement language to be credible:

If there is a stipulated dismissal, what are the implied commercial terms?

• Common settlement mechanics:
  • agreed launch date,
  • market-supply commitments pre- or post-settlement,
  • covenant not to sue for specific products,
  • “design-around” permissions.

Do settlements include indemnities or royalties?

• Some settlements include royalty or license fees that are tied to sales levels.

Is there evidence of “carve-outs” for other strengths or future filings?

• Carve-outs can matter if RK PHARMA has multiple ANDAs or intends additional formulations.

What is the Orange Book status of the asserted patents?

A correct Orange Book mapping determines infringement and exclusivity leverage:

Which NDA/ANDA is implicated?

• Identify the FDA application referenced in the complaint or in the Orange Book.

Which patents are listed as “expires” or “patent term remaining”?

• List for each patent:
  • patent number,
  • listed drug,
  • expiration date,
  • exclusivity code,
  • whether the patent is listed for method-of-use, product, or device.

Are the patents listed in a way that limits infringement theories?

• Some patents are listed for different strengths or dosage forms; mismatch reduces infringement scope.

How does RK PHARMA’s product compare with American Regent’s commercial product?

This depends on the active ingredient and formulation:

What dosage form and strength are at issue?

• Identify whether the disputed product is:
  • vial,
  • lyophilized,
  • injectable solution,
  • tablet/capsule,
  • topical/transdermal.

What labeling differences drive method-of-use claims?

• If method-of-use patents are asserted, dosing and indications matter.

What manufacturing parameters drive formulation or process infringement?

• Particle size, excipients, mixing steps, sterilization processes, and reconstitution instructions are often central.

Biosimilar or biologics angle: is this a protein product?

This section is only relevant if the drug is biologic:

• For biologics, disputes shift to Biologics Price Competition and Innovation Act (BPCIA) frameworks.
• If the case is Hatch-Waxman, it is more likely a small molecule or classic NDA/ANDA product.

What FDA pathway drives timing in this dispute?

A full analysis requires FDA application identifiers:

Is it an ANDA, 505(b)(2), or other pathway?

• ANDA generally aligns with Orange Book patent listings and paragraph IV notices.
• 505(b)(2) can change the exclusivity and patent listing relationship.

Is there a 180-day exclusivity risk?

• If RK PHARMA is first-filer or co-first-filer, “first applicant” status can change commercial entry leverage.

Key Takeaways

• The case caption and docket number alone are insufficient to identify the asserted American Regent patents, the FDA application at issue, or the litigation’s procedural posture.
• A credible litigation summary and patent estate analysis requires the complaint’s asserted patent numbers and the FDA/Orange Book mapping, which determine infringement theory, stay/exclusivity timing, and settlement leverage.

FAQs

1. What information does the complaint in 2:24-cv-11122 specify about the asserted American Regent patents?
2. How does the Orange Book listing of the NDA/ANDA patents govern infringement scope in American Regent generic disputes?
3. What procedural events typically decide launch timing in Hatch-Waxman cases like 2:24-cv-11122?
4. When do 30-month stays expire, and how do courts handle expedited schedules near expiration?
5. What settlement terms most often restrict a generic manufacturer’s design-around options?

References (APA)

1. AMERICAN REGENT, INC. v. RK PHARMA, INC., No. 2:24-cv-11122 (D. Mass. 2024).